Floatz logo

Leflunomide

Immunoglobulin G4 Related Sclerosing Disease

Chinese PLA General HospitalSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Immunoglobulin G4 Related Sclerosing Disease cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Chinese PLA General Hospital
Phase 4BB
Filgotinib
UMC Utrecht
Phase 2CCC
Bcma-Cd19 Ccar T Cells
Peking University People's Hospital
Phase 2CCC
cc-5013
Mayo Clinic
Phase 1CC
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Mayo Clinic
Phase 1CC
Mtm-H-001
Beijing GoBroad Hospital
N/AD
Lvivo-Tavec400 Product
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Early Phase 1NR

Same molecule, other indications

Leflunomide is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
64 / 100
View asset →
central nervous system neoplasmDormant
BB
Indicative ·
64 / 100
View asset →
smoldering plasma cell myelomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →